Company

Management Management

  • Management
  • Scientific Advisory Board
President Helen Cho Profile Image.
President Helen Cho

After earning her Bachelor’s degree from the Department of Biochemistry, Yonsei University and her Master’s degree in bioengineering from KAIST, Dr. Helen Cho acquired her PhD degree in molecular biology and biochemistry from the University of Medicine and Dentistry of New Jersey. Then, she completed her post-doctorate program at Salk Institute and joined Pfizer, a global pharmaceutical company, where she led the development of anticancer immunotherapy drugs based on combination therapy by using her experiences in various fields covering biological carriers and antibodies. As an Associate Research Fellow, she oversaw the research and development (R&D) of anticancer vaccines and oncolytic virus-based immunotherapy drugs as well as early clinical trials. Currently, she serves as the Director of Samyang Holdings Biopharmaceuticals Division R&D Center and President of Samyang Biopharm USA, supervising R&D in pharmaceuticals, biologics and MD businesses.

  • Professor and Chairman, Department of Oncology, Georgetown University Medical Center
  • Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
  • Professor and Leader, Department of Oncology Cancer Immunotherapy Program
  • Professor and Leader, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
  • AbbVie Foundation Professor, Cancer Immunotherapy, Departments of Pathology, Medicine and the Ben May Department for Cancer Research
  • AbbVie Foundation Professor, University of Chicago
  • Louis M. Weiner
    Louis M. Weiner
  • Lawrence Fong
    Lawrence Fong
  • Professor and Chairman, Department of Oncology, Georgetown University Medical Center
  • Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
  • Professor and Leader, Department of Oncology Cancer Immunotherapy Program
  • Professor and Leader, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
  • Thomas F. Gajewski
    Thomas F. Gajewski
  • AbbVie Foundation Professor, Cancer Immunotherapy, Departments of Pathology, Medicine and the Ben May Department for Cancer Research
  • AbbVie Foundation Professor, University of Chicago

inquiry